Weekly subcutaneous injections of the novel B-cell inhibitor obexelimab significantly reduces disease flares and lowers toxic steroid exposure in patients with active IgG4-related disease.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/b-cell-inhibitor-obexelimab-safe-effective-igg4-related-2026a1000iti?src=rss
Author :
Publish date : 2026-06-05 07:27:00
Copyright for syndicated content belongs to the linked Source.